Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday
Heron Therapeutics (NASDAQ:HRTX) is expected to report its Q4 2025 earnings before market open on Thursday, February 26th, with analysts forecasting an EPS of ($0.03) and revenue of $39.533 million. The stock currently trades around $1.21, with a market capitalization of $221.9 million, and analysts have a consensus "Hold" rating with a target price of $4.50. Institutional investors and hedge funds hold a significant 80.01% stake, with several firms increasing their positions in recent quarters.
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Heron Therapeutics will host a conference call and live webcast on February 26, 2026, at 8:30 a.m. ET to announce its fourth quarter and full year 2025 financial results and discuss recent business developments. The commercial-stage biotechnology company focuses on developing and commercializing therapeutic innovations for acute care and oncology patients. This announcement includes forward-looking statements regarding future expectations and risks.
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Heron Therapeutics, Inc. announced it will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET. The purpose of the call is to report its fourth quarter and full year 2025 financial results and discuss recent business highlights. Interested parties can register for the call or access the webcast through the company's investor relations website.
Heron Therapeutics sets Feb. 26 webcast on 2025 results, business updates
Heron Therapeutics (Nasdaq: HRTX) will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, via a conference call and live webcast at 8:30 a.m. ET. The company will discuss financial performance and recent business highlights, with a replay available on their investor website for 60 days. This announcement continues Heron's pattern of regular communication regarding its financial results and business updates.
Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden
Heron Therapeutics (NASDAQ:HRTX) carries a significant debt burden, with US$139.7m in debt against US$55.5m in cash, resulting in net debt of US$84.2m as of September 2025. The company's weak interest cover of 0.41 times and a high net debt to EBITDA ratio of 21.3 indicate a concerning level of risk despite turning a yearly EBIT loss into a gain. Investors are advised to be cautious given the substantial debt and negative free cash flow.
Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden
Heron Therapeutics (NASDAQ:HRTX) carries a significant debt burden, with net debt of US$84.2m as of September 2025. The company's weak interest cover and high net debt to EBITDA ratio raise concerns about its financial risk, despite a recent improvement in EBIT. Analysts suggest the company's reliance on debt makes it a risky investment, particularly given its negative free cash flow.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of "Hold" from Brokerages
Heron Therapeutics, Inc. (NASDAQ:HRTX) has received a "Hold" consensus rating from five brokerages. Analysts have issued an average one-year price target of $4.50 for the stock. Institutional investors have significantly increased their holdings in Heron Therapeutics, with several firms boosting their positions during the fourth quarter.
New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX
The New York State Common Retirement Fund significantly increased its stake in Heron Therapeutics, Inc. (HRTX) by 46.4% in the third quarter, acquiring 816,671 additional shares to hold a total of 2,576,716 shares valued at $3.25 million. Other institutional investors also adjusted their positions in the biotechnology company. Heron Therapeutics currently trades near its 52-week low, and analysts have an average "Hold" rating with a target price of $4.50.
Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring A 238% Upside Potential
Heron Therapeutics, Inc. (HRTX) is attracting investor interest with analysts projecting a 238.35% upside potential, setting an average target price of $4.50. The biotechnology company, specializing in therapeutic solutions using its Biochronomer technology, shows positive revenue growth despite current financial challenges like negative EPS and free cash flow. While the stock's technical indicators are neutral, strong analyst sentiment with all "buy" ratings suggests optimism for its diverse product pipeline and market expansion.
Heron Therapeutics (NASDAQ:HRTX) Stock Passes Above Two Hundred Day Moving Average - Time to Sell?
Heron Therapeutics (NASDAQ:HRTX) stock recently passed above its 200-day moving average, a technical breakout, despite mixed analyst ratings with an average price target of $4.50. The company reported a quarterly EPS loss that missed expectations and slightly lower revenue. Institutional and hedge fund ownership of the stock is significant, holding approximately 80% of shares.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of "Hold" from Analysts
Five analysts have issued an average "Hold" recommendation for Heron Therapeutics (NASDAQ:HRTX), with an average 1-year price target of $4.50. Despite significant institutional investment, including Clearline Capital increasing its stake by 1,033%, the company's near-term fundamentals appear weak, marked by a recent EPS miss and a negative P/E ratio. Shares currently trade around $1.49, falling within a 12-month range of $1.00 to $2.68.
Heron rises as preliminary revenue figures exceed estimates
This article provides an update on Heron's financial performance, noting that preliminary revenue figures have exceeded estimates. This positive news has led to an increase in the company's standing.
Great week for Heron Therapeutics, Inc. (NASDAQ:HRTX) institutional investors after losing 10% over the previous year
Heron Therapeutics, Inc. (NASDAQ:HRTX) saw a 10% stock gain last week, which is welcomed by its institutional investors, who hold a significant 57% stake in the company. Hedge funds own 27% with Rubric Capital Management LP as the largest shareholder at 16%. The general public holds 15%, while insiders own less than 1% of the US$255 million market cap company.
Heron Therapeutics’ Q4 Earnings Beat Forecasts, Boosted by Acute Care Success
Heron Therapeutics (HRTX) reported Q4 revenues exceeding forecasts, driven by strong performance from its acute care products, ZYNRELEF and APONVIE. Despite ongoing profitability concerns and a challenging market position, the company's stock rose by 12.6% due to these positive financial results and upward price momentum. The article highlights the importance of strategic focus on acute care to maintain growth and improve investor confidence.
Heron Therapeutics’ Revenue Soars Beyond Expectations in Q4 2025
Heron Therapeutics (HRTX) announced Q4 2025 revenue of $40.5 million, exceeding analyst expectations, primarily driven by strong contributions from its Acute Care franchise, particularly ZYNRELEF and APONVIE. The company's full-year 2025 net revenue reached $154.9 million, showcasing significant growth. Despite lingering profitability challenges like negative EBIT and pre-tax profit margins, the strong revenue performance and a nascent bullish technical trend for HRTX shares suggest potential for investor confidence.
Heron Therapeutics Revenue Exceeds Estimates with Strong Acute Care Performance
Heron Therapeutics (HRTX) has reported strong fourth-quarter 2025 revenue of $40.5 million, surpassing estimates, driven by its Acute Care franchise products ZYNRELEF and APONVIE. Despite this revenue growth and a high gross margin, the company faces significant profitability and financial strength challenges, including negative EBIT and profit margins, substantial debt, and a cautious market outlook. The stock has shown recent upward momentum, with key technical levels to watch for future movements.
Heron Therapeutics Surpasses Revenue Expectations with Significant Growth
Heron Therapeutics (HRTX) has seen its stock rise by 12.6% due to positive FDA feedback and strong quarterly revenues, particularly from its acute care products ZYNRELEF and APONVIE. While revenue growth is promising, the company still faces challenges with profitability and high leverage, indicating a need to focus on operational efficiencies and cost management to achieve sustained success. Analysts maintain a cautiously optimistic outlook, setting a price target of 1.50 for the stock.
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M
Heron Therapeutics reported preliminary Q4 2025 revenue of approximately $40.5M, exceeding the consensus estimate of $39.83M, driven by strong growth in its Acute Care franchise with ZYNRELEF and APONVIE. The company's CEO, Craig Collard, expressed satisfaction with the revenue growth and overall business progress throughout the past year, with ZYNRELEF showing the largest quarter-over-quarter increase. Full-year 2025 net revenue reached approximately $154.9M.
Heron Therapeutics Expands Strategic Vision Amid Market Fluctuations
Heron Therapeutics (NASDAQ: HRTX) saw its stock rise by 12.6% due to optimistic FDA-related news. The company is adopting a dynamic strategic vision, navigating financial challenges with calculated risk-taking and innovation, as indicated by its latest quarterly report and speculation around potential new collaborations. Despite operational costs and a high debt-to-equity ratio, Heron Therapeutics aims for financial agility and strategic expansion.
Heron Therapeutics' (HRTX) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright has reiterated a "Buy" rating for Heron Therapeutics (HRTX) with a price target of $6.00, suggesting a significant upside of over 300%. This re-affirmation comes despite mixed analyst coverage, which currently averages a "Hold" rating, and the company recently missed quarterly EPS and revenue estimates. Institutional investors hold approximately 80% of Heron Therapeutics' stock.
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
Heron Therapeutics announced preliminary unaudited net revenues for Q4 and full-year 2025, reaching approximately $40.5 million and $154.9 million, respectively. ZYNRELEF was the largest contributor to Q4 growth, showing a 35% increase over Q3 2025. The company highlighted strong performance across its Acute Care franchise, including APONVIE, and overall business progress throughout the year.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts
Heron Therapeutics, Inc. (NASDAQ:HRTX) has received an average "Hold" recommendation from analysts, with a consensus 1-year target price of $4.50. The company recently reported a quarterly EPS miss and revenue below expectations, with the stock currently trading around $1.28. Institutional investors hold approximately 80% of the shares, while the stock has seen a recent decline of 4.5%.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Heron Therapeutics, Inc. (NASDAQ:HRTX) shares have recently surged by 27%, yet the stock remains down 15% over the past year. The company's price-to-sales (P/S) ratio of 1.7x is significantly lower than the industry average, primarily due to sluggish revenue growth and a forecast for future growth that lags behind the broader biotech industry. This subdued outlook on revenue seems to be the main factor contributing to its low P/S ratio and limited near-term share price appreciation.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Heron Therapeutics (NASDAQ:HRTX) shares surged 27% recently, yet the stock remains down 15% over the past year. Despite a low price-to-sales (P/S) ratio of 1.7x compared to the biotechnology industry average, the company's revenue growth of 13% over the last year and 58% over three years is expected to slow to 14% annually, lagging the industry's projected 132% growth. This muted future growth outlook appears to be the primary reason for its depressed P/S ratio and could hinder significant share price appreciation in the near term.
Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the company
Institutional investors currently hold 57% ownership in Heron Therapeutics, Inc. (NASDAQ:HRTX), indicating a significant level of confidence and potential influence on the company's stock performance. Hedge funds specifically control 27% of the shares, with Rubric Capital Management LP being the largest single shareholder at 16%. The general public holds a 15% stake, while company insiders own less than 1% of the shares.
Heron Therapeutics Stock Jump Looks Great, But How Secure Is That Gain?
The article poses a question about the sustainability of Heron Therapeutics' stock gains. It appears to be an interactive financial model page from Trefis, focused on analyzing the company's stock performance and underlying drivers. However, the provided content is largely boilerplate and lacks specific details about Heron Therapeutics' financial health or stock performance.
Market Sentiment Around Loss-Making Heron Therapeutics, Inc. (NASDAQ:HRTX)
Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, is nearing a significant business achievement as it approaches breakeven. Analysts predict the company will generate positive profits of US$3.7m in 2026, breaking even just over a year from now, requiring an estimated 69% year-on-year growth. However, the company faces a high debt-to-equity ratio of over 2x, which suggests increased risk due to stringent capital management.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Consensus Recommendation of "Hold" by Analysts
Heron Therapeutics, Inc. (NASDAQ:HRTX) has received a consensus "Hold" recommendation from analysts, with an average one-year price target of $4.50. The company missed Q3 estimates, reporting an EPS of ($0.05) and revenue of $38.21M, while institutional investors now own approximately 80.01% of the stock. Shares are currently trading around $1.15, and analysts anticipate an EPS of approximately -$0.13 for the year.
Heron Therapeutics Announces Inclusion of APONVIE® Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
Heron Therapeutics announced that APONVIE® (aprepitant) injectable emulsion is included in the new Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV). The guidelines highlight APONVIE as the only FDA-approved IV formulation Neurokinin-1 antagonist for PONV prevention, noting its long half-life and quicker onset. This inclusion reinforces APONVIE's role in improving patient outcomes by reducing post-surgical complications, particularly in outpatient and short-stay settings.
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
Heron Therapeutics, Inc. announced that its injectable emulsion APONVIE® (aprepitant) has been included in the Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV). APONVIE is highlighted as the only FDA-approved IV formulation Neurokinin-1 antagonist for PONV prevention in adults, offering a quicker onset and long-lasting protection. The guidelines emphasize the importance of long-acting antiemetic strategies to protect patients from nausea and vomiting extending beyond hospital discharge.
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
Heron Therapeutics announced that APONVIE® (aprepitant) injectable emulsion has been included in the newly released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV). The guidelines highlight APONVIE as the only FDA-approved IV formulation neurokinin-1 antagonist for PONV prevention, noting its long half-life and quicker onset than oral aprepitant. This inclusion is significant as PONV affects millions of patients and can cause considerable distress, making effective prevention crucial for patient recovery, especially in outpatient settings.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported, And Analysts Assigned A US$4.50 Price Target
Heron Therapeutics, Inc. (NASDAQ:HRTX) recently reported its third-quarter results, missing analyst revenue predictions but maintaining EPS forecasts, leading to a reduced average price target of US$4.50. Analysts lowered revenue estimates for 2026, indicating a less optimistic outlook despite stable earnings projections. The company's revenue growth is expected to slow compared to historical rates and the broader industry.
Heron Therapeutics (HRTX): Forecasts Signal 60.89% Annual Earnings Growth, Path to Profitability in Focus
Heron Therapeutics (HRTX) has significantly narrowed its losses over the past five years and is projected to achieve profitability within the next three years, with earnings expected to grow 60.89% annually. The company's revenue is also forecast to rise, exceeding the US market average. Despite a low Price-To-Sales ratio compared to industry benchmarks, improved financial flexibility from recent financing and operational restructuring are anticipated to drive margin expansion and potentially re-rate its stock.
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Heron Therapeutics, Inc. (Nasdaq: HRTX) has announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack brings over 20 years of experience in investment management and corporate finance, including a significant tenure as Managing Director at Starboard Value LP. His appointment is pursuant to a Cooperation Agreement between the Company and Rubric Capital Management LP and is expected to contribute valuable perspective to Heron's growth efforts.
Heron Therapeutics: Stagnant Cash Cow, Blockbuster That Wasn't - Steer Clear
Heron Therapeutics (HRTX) is rated a "Hold" due to its middling performance and lack of immediate growth catalysts. The company's oncology franchise is declining, while its acute care franchise, though showing growth, remains small with a key product launch not expected until 2027. Despite a low cash burn providing runway into 2027, future financing will likely be necessary before any significant product-driven turnaround.
Heron Therapeutics Inc. Q3 Loss Increases, Misses Estimates
Heron Therapeutics Inc. (HRTX) reported a Q3 loss of -$17.50 million, or -$0.10 per share, which is an increase from -$4.85 million, or -$0.03 per share, in the same period last year and missed analyst estimates of -$0.01 per share. The company's revenue for the quarter rose by 16.5% to $38.21 million from $32.81 million year-over-year.
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
Heron Therapeutics announced robust financial results for Q3 2025, with total net revenue reaching $38.2 million and year-to-date revenue of $114.3 million. The company reaffirmed its 2025 net revenue guidance of $153 million to $163 million and adjusted EBITDA guidance of $9.0 million to $13.0 million, driven by significant growth in ZYNRELEF and APONVIE sales due to new commercial initiatives and product enhancements.
Heron Therapeutics, Inc. Appoints Thomas Cusack to Board of Directors
Heron Therapeutics, Inc. announced the appointment of Thomas Cusack to its Board of Directors, effective October 27, 2025, as part of a Cooperation Agreement with Rubric Capital Management LP. Mr. Cusack brings over 20 years of experience in corporate finance, investment management, and corporate governance from roles at Starboard Value LP, Barclays Capital, and Lehman Brothers. His appointment is expected to enhance Heron's strategic direction and corporate governance, particularly in advancing its therapeutic innovations in acute care and oncology.
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Heron Therapeutics, Inc. announced the appointment of Thomas Cusack to its Board of Directors, effective October 27, 2025. Mr. Cusack brings over 20 years of experience in investment management and corporate finance, including a significant tenure as Managing Director at Starboard Value LP. His appointment is pursuant to a Cooperation Agreement with Rubric Capital Management LP and is expected to contribute significantly to Heron's strategic efforts.
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Heron Therapeutics, Inc. announced it will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to release its third quarter 2025 financial results and discuss recent business developments. Interested parties can access the call via a registration link for dial-in details or through a webcast available on the Investor Relations section of Heron's website. An archive of the event will be available for 60 days following the call.
Heron Therapeutics Approves Stock Issuance Proposals - TipRanks
Heron Therapeutics stockholders approved proposals to issue common stock exceeding 19.99% of outstanding shares. These approvals are linked to future conversions of convertible senior unsecured promissory notes and Series A Convertible Preferred Stock. The company, which focuses on pain management and cancer care, faces financial challenges despite strong revenue growth.
Heron Therapeutics shareholders approve convertible securities issuances By Investing.com - Investing.com UK
Heron Therapeutics shareholders have approved the issuances of convertible securities. This decision was made during a recent shareholder meeting.
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
Heron Therapeutics, Inc. has adopted a Tax Benefits Preservation Plan, specifically a Section 382 rights plan, to protect its substantial net operating loss carryforwards (NOLs). This plan aims to deter any single investor or group from acquiring 4.99% or more of the company's stock, which could trigger an "ownership change" under Section 382 of the Internal Revenue Code and limit the use of these valuable tax assets. The company's NOLs, totaling approximately $1.37 billion as of December 31, 2024, are crucial for offsetting future taxable income and supporting its growth strategy.
Latham Watkins Advises on Heron Therapeutics Credit Restructuring Senior Credit US150 Million
Latham & Watkins advised Hercules Capital on a comprehensive capital restructuring for Heron Therapeutics, a commercial-stage biotechnology company. This restructuring aims to enhance Heron's financial flexibility, reduce debt, and support long-term growth through a new senior credit facility totaling US$150 million, an exchange agreement for existing notes, new convertible notes, and a private placement. The multidisciplinary team from Latham & Watkins was led by partners Dan Van Fleet and Haim Zaltzman for finance, Eric Rice for capital markets, and Eric Cho for tax matters.
Heron Therapeutics: Middling Performance From Approved Therapies With No Pipeline
Heron Therapeutics (HRTX) is rated as a "Hold" due to limited growth prospects, the absence of a pipeline, and no clear strategic direction. While ZYNRELEF and APONVIE are current growth drivers, they face future patent expiration. The company also faces liquidity challenges with significant debt maturing in May 2026, which will likely necessitate dilutive financing.
Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Heron Therapeutics, Inc. (NASDAQ:HRTX) exceeded analyst revenue and profit forecasts for its latest quarter, reporting US$39m in revenue and an unexpected statutory profit of US$0.01 per share. Despite reconfirming revenue estimates for 2025, analysts significantly increased per-share loss forecasts, yet raised the price target by 5.6% to US$6.33, suggesting long-term optimism. The company is expected to see accelerated revenue growth compared to its historical performance, though still slower than the broader industry.
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
Heron Therapeutics reported strong Q1 2025 financial results, generating $38.9 million in net revenue and a record Adjusted EBITDA of $6.2 million. The company raised its full-year 2025 Adjusted EBITDA guidance to $4 - $12 million and highlighted key business achievements including a patent settlement with Mylan Pharmaceuticals for CINVANTI and APONVIE, and the successful launch of the ZYNRELEF VAN.
Lacklustre Performance Is Driving Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 26% Price Drop
Heron Therapeutics' stock price has dropped 26% in the last 30 days due to sluggish performance and an underwhelming revenue outlook, leading to a low price-to-sales (P/S) ratio of 1.9x compared to an industry average of 8.8x. Analysts forecast a 13% annual revenue growth for Heron over the next three years, significantly lower than the industry's projected 173%, contributing to the company's depressed P/S and current shareholder discontent. Investors are advised to consider warning signs and the company's future prospects before making investment decisions.
San Diego Biotech Firm Heron Therapeutics Shifts Operations to North Carolina
Heron Therapeutics, Inc., a biotechnology company, has announced the relocation of its headquarters from Sorrento Valley, San Diego, to Cary, North Carolina, effective January 1, 2025. This move is driven by a majority of its management and corporate employees already working from Cary and the area's growing biotech community near Research Triangle Park. CEO Craig Collard stated the shift as a significant milestone, aiming to strengthen operations, centralize resources, and foster strategic partnerships for its portfolio focused on acute and oncology care.
California public company relocates to North Carolina
Heron Therapeutics, a biotech company led by former Veloxis and Salix executives, is moving its headquarters from California to Cary, North Carolina. This relocation involves establishing an office building at 100 Regency Forest Drive in Cary, Wake County. The move signifies a significant corporate relocation from California to the Triangle area.
